Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses of $(19.74) per share from the same period last year. The company reported quarterly sales of $10.844 million which beat the analyst consensus estimate of $4.000 million by 171.10 percent.